McKenzie M, McLemore T, Rankin P, Martin R R, Wray N, Cantrell E, Busbee D
Cancer. 1978 Dec;42(6):2733-7. doi: 10.1002/1097-0142(197812)42:6<2733::aid-cncr2820420631>3.0.co;2-v.
A component capable of binding benzo(a)pyrene was measured in plasma from cigarette smokers and nonsmokers. This plasma fraction was found to have a high specificity of binding to benzo(a)pyrene, bound benzanthracene competitively with benzo(a)pyrene, and was positively correlated (r = 0.861, p less than 0.001) with the capacity of the individual subject's lymphocytes to be induced for AHH activity in culture. An inverse correlation (r = -0.957, p less than 0.001) between the presence of the plasma component in lung cancer patients and the capacity of lung cancer patients' lymphocytes to be induced in culture is unexplained at this time. A benzo(a)pyrene-binding fraction was not found in induced or uninduced cultured lymphocytes from smokers or nonsmokers, or in homogenates of lung excisional tissue from smokers with or without primary lung cancer.
在吸烟者和非吸烟者的血浆中检测到一种能够结合苯并(a)芘的成分。发现这种血浆组分对苯并(a)芘具有高度特异性结合，能与苯并(a)芘竞争性结合苯并蒽，并且与个体受试者淋巴细胞在培养中被诱导产生芳烃羟化酶（AHH）活性的能力呈正相关（r = 0.861，p小于0.001）。肺癌患者血浆中该组分的存在与肺癌患者淋巴细胞在培养中被诱导的能力之间呈负相关（r = -0.957，p小于0.001），目前尚无法解释。在吸烟者或非吸烟者经诱导或未经诱导的培养淋巴细胞中，以及在患有或未患有原发性肺癌的吸烟者的肺切除组织匀浆中，均未发现苯并(a)芘结合组分。
